Today’s AI Top Pick: SPRO

7/27/2026 · Contrarian screen · a free sample of K3vl4r’s AI-curated picks.

AI-ranked from a screened shortlist, with entry strategy, targets, and risks.

Today's pick · ContrarianSPROBUY NOW8.7 / 107/27/2026

SPRO is the standout contrarian bounce today: it combines the deepest oversold condition (RSI 20.9, -45.4% drawdown, position_in_21bar_range 0-2.7% across every timeframe) with the best fundamentals in the pool (fundamental_score 8, PE 4.88, fwdPe 1.78, profit margin 27.82%, ROE 35.12) AND a genuine, dated positive catalyst — the July 15 Innovent licensing deal for IBI355 worth up to $1.1B, which for a $69M market-cap company is transformative and explains the crushed base rather than a broken thesis. The selling here looks like post-catalyst profit-taking exhaustion, not a broken trend. Multi-timeframe forecast alignment is exceptional on the sub-weekly frames: 1h forecasts +114.7/+111.9/+146.8%, 4h +121.6/+108.8/+96.2%, 1d +59.0/+98.7/+82.5%. Kronos bullish probability is 1.0. The one blemish is 1wk short/mid at -18%, but long-term weekly still flips to +33.2%, consistent with a base-and-turn pattern rather than continued breakdown. Combined near_term_bullish score is 0.6, and expected_return_pct is +79.8. Critically, price sits at position 0 in the 1h and 4h ranges and only 2.7% off the 21-bar low on the daily — you are not chasing. Waiting risks missing the mean reversion snap given how compressed RSI and price are, and the Innovent deal provides fundamental floor rationale for institutional buyers to defend the $1.10-1.15 area. Biggest counterweight: micro-cap biotech, salesYoY +93.5% but future revenues depend on Innovent milestones; secondary offering risk is non-trivial. Still, versus JUNS (extreme fundamentals rot), DARE (-1038% profit margin), BTCT (dilution announced), IBM (analyst PT cuts, weekly negative), and ACI/QS (52-week lows with fresh downgrades), SPRO offers the cleanest combination of exhausted selling, real catalyst, and value fundamentals.

Entry zone

$1.15 - $1.22 (buy immediately; scale in aggressively if it dips to $1.10-1.15 intraday)

Stop loss

$0.98 close (breaks the recent low structure and invalidates the post-Innovent-deal base; ~18% risk)

First target

$1.80 (short-covering / gap fill area, +51%)

Longer target

$2.40 - $2.75 (analyst target upside implies +236%; conservative swing target is prior consolidation zone, ~+100-130%)

Risks

Micro-cap ($69M) biotech — a single ATM/secondary announcement could dilute 20-40% overnight
1wk short/mid forecasts still negative (-18.1%/-17.6%), meaning higher-timeframe trend hasn't confirmed the turn yet
Recom score is 3.0 (Hold) — analyst community not yet enthusiastic despite the Innovent licensing news
Sector risk: small-cap biotech sentiment fragile; a broad healthcare selloff can override single-name catalyst
Position at 0% of 21-bar range means no confirmed higher-low structure yet — could grind sideways before bouncing

Honorable mentions

DARECleanest multi-timeframe forecast alignment in the pool (all four TFs positive: 1h +104/+101/+113, 4h +54/+65/+58, 1d +68/+82/+58, 1wk +64/+58/+46), position at bottom of range (6.74%/1.76%), near_term_bullish 1.0. Held back by ugly fundamentals (profit margin -1038%, debt/equity 9.84) and no clear positive catalyst — a technical bounce trade only.

SPIRSolid fundamentals (fund score 5.75, PE 6.99, ROE 100.58), fresh positive catalyst (10-satellite SpaceX launch, SeekingAlpha bullish note), 1h/4h/1d forecasts all positive (+64/+60/+83, +40/+35/+13, +1/+20/+15). Only -21% drawdown so less coiled spring, and 1wk short is -8%.

Full ranking (29)

#	Symbol	Verdict	Score	Read
1	SPRO	BUY NOW	8.7	Deepest oversold (RSI 20.9) + $1.1B Innovent licensing catalyst + best fundamentals in the pool (fwdPe 1.78, PM 27.8%) at 0% of range.
2	DARE	BUY NOW	7.6	Cleanest multi-TF forecast alignment (all four TFs positive) at bottom of range; pure technical bounce trade with weak fundamentals.
3	SPIR	BUY NOW	7.4	Positive satellite launch catalyst, fund score 5.75, ROE 100.58, 1h/4h/1d forecasts all up though drawdown only -21%.
4	BESS	BUY PULLBACK	7.1	Strong forecasts on 4h/1d/1wk (+52/+107/+123 long), fund score 6, fwdPe 2.44, but 1h near-term flat suggests wait for dip.
5	INV	BUY PULLBACK	6.9	Multi-TF forecasts strong (1h +103/+100/+118, 1wk +33/+137/+72), recom 1.0, but PS 74 stretched and CEO transition creates uncertainty.
6	AKTX	BUY PULLBACK	6.5	Maxim upgrade to Buy $30 PT and 1d fc +107/+115, but 1wk forecasts show -100 anomaly and 1h mid/long negative — mixed TF signal.
7	LTRN	BUY PULLBACK	6.3	USPTO patent allowance is a real positive, 1d/1wk forecasts +31/+21 and +9/+54/+55, but only -20% drawdown limits bounce magnitude.
8	TEM	BUY PULLBACK	6.2	Cathie Wood buying, 1d +31/+58/+40, all four TFs positive mid-horizon, but at 28% of 1h range so entry is already extended.
9	BTCT	WAIT	6.0	Huge forecasts (1wk +209/+391) but recent private placement = dilution overhang on $6M micro-cap.
10	CRML	BUY PULLBACK	5.9	1h/4h/1d forecasts all positive (+90/+83, +54/+84/+60), rare earth thesis intact but recent asset review and disregarded press release create noise.
11	LBRT	WAIT	5.7	Best-scored energy name but two analyst PT cuts on July 24 and 1wk forecasts -6/+1/-22 undercut the bounce thesis.
12	SST	BUY PULLBACK	5.6	1d forecasts +91/+114/+137 are huge, but fund score 0 and micro-cap illiquidity ($18M) create execution risk.
13	LUCY	WAIT	5.4	Claude AI integration is a narrative catalyst and 1d fc +18/+78/+100, but recent warrant exercise = dilution and $5.6M mkt cap = risk.
14	GRRR	WAIT	5.2	$232M in bond financing is dilutive optics despite AI infrastructure narrative; 1h/1d forecasts moderate at best.
15	JUNS	WAIT	5.0	$100M ALA-002 licensing deal is real but 1d mid forecast -0.3% and profit margin -22690% make this a lottery ticket.
16	QS	WAIT	4.8	Q2 earnings sell-off, TD Cowen PT cut to $6, fresh 52-week lows — fighting active downgrade cycle despite forecast signal.
17	RUN	WAIT	4.7	Tesla energy-adjacent selloff pressure, high debtEq 4.45, epsNextY -61.6 — forecasts positive but macro headwind.
18	INTZ	WAIT	4.6	1d up +10.6% already, position 19% of range so not oversold, and fundamentals awful (PM -169%).
19	IBM	AVOID	4.4	'IBM Fell 25% as Hardware Spending Dominated AI Budgets' — fundamental thesis broken; 1wk forecasts negative (-2/-13/-18).
20	TVRD	WAIT	4.3	ATM offering announcement is direct dilution risk despite huge 1wk forecast (+889/+986).
21	EOSE	AVOID	4.1	Hit 52-week low July 23 with $263M raise = fresh dilution; forecast strong but capital structure damage recent.
22	ALOY	WAIT	4.0	Needham PT cut to $16 and PS 189 grossly stretched; 1wk forecasts flat (+1/+2/-0.7).
23	YCBD	WAIT	3.9	Only near_term_bullish 0.2, no 1wk data, and $5.6M mkt cap is untradeable size.
24	EVH	AVOID	3.7	Citigroup downgrade to Neutral July 23 and 'Stock is Nosediving' headline; 1h/4h forecasts negative.
25	ACI	AVOID	3.5	BMO downgrade July 25 + 52-week low + 'sobering reveal' headline — active downgrade cycle overrides bounce.
26	AIIO	AVOID	3.2	Fund score -3.25, profit margin -17614%, salesYoY -92% — pure lottery ticket with no real business.
27	SG	AVOID	3.0	Fund score -1.5, epsNextY -572%, 1wk forecasts negative (-4.7/-13.3); no clean catalyst.
28	RPD	AVOID	2.8	Morgan Stanley cybersecurity caution, targetUpsidePct -15.2%, forecasts modest.
29	NN	AVOID	2.6	PS 421, PM -3506%, fund score -2.5; upgrade is on 'Spartacus Acquisition' not the operating business.

Get AI top picks & forecasts on any stock

K3vl4r screens the market daily and ranks the best setups with AI — forecasts, scored fundamentals & technicals, and multi-horizon price targets. Create a free account to explore them all.

Create your free account →

Already a member? Sign in · Join our Discord